US SEC Trading Suspension Halt Orders — September 16, 2026

Successfully regained compliance with NYSE American minimum stockholders' equity rule after two consecutive quarters of improvement, ahead of the November 30, 2026 deadline. This is the only positive compliance event in the cohort and signals operational stabilization

Imminent trading suspension on September 18, 2026, following Chapter 11 bankruptcy filing on September 4. This is a terminal delisting event with zero recovery prospects for equity holders

Received Nasdaq deficiency notice for failing the Minimum Public Holders Rule (400 holders required). Has 45 days to submit a compliance plan, with a potential 180-day extension. The SPAC structure adds complexity to regaining compliance

Failed minimum bid price of $1 for 30 consecutive days. Has until March 9, 2027 to cure via reverse stock split, which requires stockholder approval at the upcoming annual meeting. Dilution risk is high

Received Nasdaq extension until December 2, 2026 to meet $2.5M minimum stockholders' equity. Previously failed alternative listing standards, making compliance uncertain. The short deadline (77 days from filing date) creates urgency

Potential for a second 180-day compliance period if it meets other continued listing requirements, providing a longer runway than peers. This optionality reduces immediate delisting risk [NEUTRAL/BULLISH]

Nasdaq notice does not currently impact trading of securities, providing a window for the company to address the deficiency without immediate market disruption

Must publicly demonstrate compliance by December 2, 2026, creating a binary catalyst. Failure triggers delisting determination with appeal rights, offering a potential second chance [NEUTRAL/BEARISH]

Trading will be suspended on September 18, 2026, just 2 days after this filing. Equity holders face total loss as the company enters Chapter 11 bankruptcy. This is the highest-risk event in the cohort

Stock has traded below $1 for 30 consecutive days. The proposed reverse stock split requires stockholder approval, which may not pass. If the split fails, delisting is likely by March 9, 2027

Must demonstrate $2.5M minimum stockholders' equity by December 2, 2026. The company has already failed alternative listing standards, suggesting severe financial distress. The 77-day deadline is tight

Only 45 days to submit a compliance plan (deadline October 26, 2026). As a SPAC, the company may struggle to attract and maintain 400 public holders, especially post-de-SPAC

The reverse stock split, if approved, will reduce share count but does not address underlying business fundamentals. The company remains pre-revenue with no forward-looking guidance, increasing bankruptcy risk

Nasdaq specifically cited residual equity holder concerns in the delisting notice, indicating potential litigation or regulatory issues beyond the bankruptcy filing

Even if delisted, the company has appeal rights to a Nasdaq Hearings Panel, but success is not assured. The process could extend uncertainty for months

The filing explicitly states there is no assurance the company will regain or maintain compliance, highlighting the binary nature of the outcome

Successfully regained NYSE American compliance ahead of deadline, removing the 'noncompliant' indicator. This could attract new institutional investors who were previously restricted from holding noncompliant securities

Has until March 9, 2027 to cure, with potential for a second 180-day extension. This long runway provides time for operational improvements or a strategic transaction to boost share price naturally

The 45-day compliance plan submission window and potential 180-day extension create a catalyst timeline. If the company finds a business combination partner or attracts additional holders, the stock could re-rate

Received a second chance with a December 2, 2026 deadline. If the company can raise equity or restructure to meet the $2.5M requirement, the stock could recover from distressed levels

The removal from the noncompliant list could signal a broader turnaround in the energy sector, particularly for small-cap E&P companies that have stabilized operations

If the reverse stock split is approved and executed, the stock may trade above $1 temporarily, attracting momentum traders and potentially triggering a short squeeze

If the compliance plan is rejected, the company can appeal to a Nasdaq Hearings Panel, providing an additional avenue to avoid delisting and potentially extending the timeline

Similar to Aldel, the company can appeal a delisting determination, providing optionality and time for a strategic alternative

4 of 5 filings (80%) involve micro-cap companies facing delisting risks, suggesting a broader capital market tightening for small, unprofitable firms. This pattern is consistent with rising interest rates and risk aversion in equity markets

2 of 5 filings (Bone Biologics, Exicure) are in the biotechnology sector, which is chronically capital-intensive and cash-burning. These companies face structural challenges in maintaining listing standards without regular capital raises

Aldel Financial II, a SPAC, highlights the unique risks of blank-check companies post-de-SPAC, where maintaining 400 public holders can be challenging if the business combination fails to attract retail interest

Synergy CHC Corp's Chapter 11 filing triggered an automatic delisting, demonstrating that bankruptcy is the most definitive path to trading suspension. This contrasts with deficiency notices that offer cure periods

Battalion Oil Corp's successful compliance regain shows that companies can resolve listing deficiencies through operational improvement. This provides a potential template for other distressed issuers

The concentration of Nasdaq and NYSE American deficiency notices in a single day (September 10-11, 2026) may indicate increased exchange scrutiny on listing standards, potentially signaling a broader crackdown on noncompliant issuers

Trading suspension on September 18, 2026. Monitor for any last-minute appeals or bankruptcy court rulings that could delay the delisting

Compliance plan submission deadline is October 26, 2026. Watch for the plan details and Nasdaq's acceptance decision within 45 days

Compliance deadline is December 2, 2026. Monitor for any equity raises or restructuring announcements in the next 77 days

Annual meeting date TBD for reverse stock split vote. Watch for proxy filing and stockholder sentiment on the proposed split

Monitor for any subsequent filings confirming sustained compliance and potential reinstatement to NYSE American's compliant list

Watch for any additional deficiency notices or delisting actions in the coming weeks, which could signal a broader regulatory trend

Monitor for similar bid price or equity deficiency notices among other small-cap biotech firms, which could indicate sector-wide distress